Soluble guanylate cyclase modulators—a novel therapeutic approach for diabetic kidney disease

Diabetic kidney disease (DKD) is a common complication, affecting approximately 40% of patients with diabetes and imposing substantial health and economic burdens worldwide. As DKD prevalence rises, existing treatments remain limited in efficacy, necessitating innovative therapeutic strategies. Soluble guanylate cyclase (sGC) modulators, including activators and stimulators, have emerged as promising treatments by enhancing cyclic guanosine monophosphate production, thereby exerting vasodilatory, anti-inflammatory, and anti-fibrotic effects. Preclinical studies have demonstrated their efficacy in improving renal function and reducing proteinuria in DKD models. Notably, clinical trials involving sGC activators, such as avenicguat, suggest potential benefits in managing DKD, particularly in combination with renin-angiotensin-aldosterone system inhibitors. While initial findings indicate renal protection and good tolerability, further large-scale studies are needed to confirm long-term efficacy and safety. The development of sGC modulators offers hope for improving DKD outcomes and reducing its global healthcare burden.